ARTHROTEC 50 TABLET (DELAYED-RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

DICLOFENAC SODIUM; MISOPROSTOL

から入手可能:

PFIZER CANADA ULC

ATCコード:

M01AB55

INN（国際名）:

DICLOFENAC, COMBINATIONS

投薬量:

50MG; 200MCG

医薬品形態:

TABLET (DELAYED-RELEASE)

構図:

DICLOFENAC SODIUM 50MG; MISOPROSTOL 200MCG

投与経路:

ORAL

パッケージ内のユニット:

250

処方タイプ:

Prescription

治療領域:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

製品概要:

Active ingredient group (AIG) number: 0222885001; AHFS:

認証ステータス:

APPROVED

承認日:

2001-02-07

製品の特徴

_Product Monograph _
_ _
_ARTHROTEC (diclofenac sodium and misoprostol) _
_Page 1 of 46_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ARTHROTEC
® 50
diclofenac sodium and misoprostol enteric-coated tablets
50 mg diclofenac/200 mcg misoprostol, Oral
PR
ARTHROTEC
® 75
diclofenac sodium and misoprostol enteric-coated tablets
75 mg diclofenac/200 mcg misoprostol, Oral
NSAID with a Mucosal Protective Agent
Pfizer Canada ULC
17,300 Trans Canada Highway
Kirkland, QC H9J 2M5
Date of Initial Authorization:
JAN 15, 1993
Date of Revision:
FEB 13, 2024
Submission Control Number: 279263
Wyeth Holdings LLC
®
Pfizer Canada ULC, Licensee
©
Pfizer Canada ULC
_ _
_Product Monograph _
_ _
_ARTHROTEC (diclofenac sodium and misoprostol) _
_Page 2 of 46_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
02/2022
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
02/2022
7 WARNINGS AND PRECAUTIONS, Skin
02/2022
7 WARNINGS AND PRECAUTIONS, Skin
02/2024
7 WARNING AND PRECAUTIONS, 7.1.1 pregnant women
02/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................